The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Divasa in the treatment and prevention of cerebrovascular diseases

Read: 4712 times


To cite this article:

Divasa in the treatment and prevention of cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12):111‑115. (In Russ.)
https://doi.org/10.17116/jnevro2017117121111-115

Recommended articles:
Primary progressive apha­sia in the neurologist practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):61-66
Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80
Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Conscious seda­tion with benzodiazepines in pediatric outpatient dentistry. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):55-63
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37

References:

  1. Shchepankevich LA. Ischemic stroke in patients with diabet type 2: blood and vascular wall [abstract of dissertation]. Novosibirsk. 2014. On 01.06.17 (In Russ.) http://vak.ed.gov.ru/dis-details?xPARAM=172987
  2. Fateeva VV, Vorob’eva OV. Cerebral markers of endothelial dysfunction in chronic brain ischemia. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2017;117(4):106-110. (In Russ.) https://doi.org/10.17116/jnevro201711741106-110
  3. Fateeva VV, Vorob’eva OV, Glazunov AB. Endothelial dysfunction is a pharmacological target for therapy of affective disorders in patients with cardiovascular diseases. Consilium Medicum. 2017;117:19(2.1):84-88. (In Russ.)
  4. Shavlovskaya OA. Clinical efficacy of neuropeptides in cerebrovascular pathology. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2016;116(8):88-93. (In Russ.) https://doi.org/10.17116/jnevro20161168188-93
  5. Skoromets AA, Stakhovskaya LV, Belkin AA, Shekhovtsova KV, Kerbikov OB, Burenchev DV, Gavrilova OV, Skvortsova VI. New possibilities of neuroprotection in the treatment of ischemic stroke. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2008;22(108):32-38. PMID: 19431244. (In Russ.)
  6. Trailin AV, Levada OA. Protein S100B: neuroscience, the importance in neurological and psychiatric disease. International neurological journal. 2009;3:1(23):166-172. (In Russ.)
  7. Lasič E, Galland F, Vardjan N, Šribar J, Križaj I, Leite MC, Zorec R, Stenovec M. Time-dependent uptake and trafficking of vesicles capturing extracellular S100B in cultured rat astrocytes. J Neurochem. 2016;139(2): 309-323. https://doi.org/10.1111/jnc.13754
  8. Sherstnev VV, Yurasov VV, Gruden MA, Yakovleva NE, Storozheva ZI, Proshin AT, Puzyrev AV. Biochemical markers of apoptosis in the brain of «intact» rats and after the central application of S100b protein. Neurochemistry. 2004;21(2):110-114. (In Russ.)
  9. Sandweiss AJ, Azim A, Ibraheem K, Largent-Milnes TM, Rhee P, Vanderah TW, Joseph B. Remote ischemic conditioning preserves cognition and motor coordination in a mouse model of traumatic brain injury. J Trauma Acute Care Surg. 2017. https://doi.org/10.1097/TA.0000000000001626
  10. Welch RD, Ellis M, Lewis LM, Ayaz SI, Mika VH, Millis S, Papa L. Modeling the kinetics of serum glial fibrillary acidic protein, ubiquitin carboxyl-terminal hydrolase-L1, and S100b concentrations in patients with traumatic brain injury. J Neurotrauma. 2017;34(11):1957-1971. https://doi.org/10.1089/neu.2016.4772
  11. Liswati E, Wijaya A, Ranakusuma TAS. Biochemical markers for differential diagnosis of stroke: a biochemical markers study of S100b protein, neuron spesific enolase (NSE), myelin basic protein (MBP), and heart-type fatty acid binding protein (H-FABP). The Indonesian Biomedical Journal. 2009;1(1):68. https://doi.org/10.18585/inabj.v1i1.85
  12. Li Y, Yu ZX, Ji MS, Yan J, Cai Y, Liu J, Yang HF, Jin ZC. A pilot study of the use of dexmedetomidine for the control of delirium by reducing the serum concentrations of brain-derived neurotrophic factor, neuron-specific enolase, and S100b in polytrauma patients. J Intensive Care Med. 2017: 885066617710643. https://doi.org/10.1177/0885066617710643
  13. Tanaeva KK, Dugina YuL, Kachaeva EV, Epshteyn OI. Prospects of the novel combined drug divaza in the pathogenetic treatment of chronic cerebral ischemia. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2014;114(9):94-98. PMID: 25473662. (In Russ.)
  14. Vorob’eva ОV, Fateeva VV. Divazа in the treatment of cerebrovascular disease: the mechanism of drug action and indications to its administration. Psychiatry. 2015;2:45-54. (In Russ.)
  15. Kamchatnov PR, Vorob’eva OV, Rachin AP. Treatment of emotional and cognitive disorders in patients with chronic cerebral ischemia. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2014;114(4):52-56. PMID: 24874318. (In Russ.)
  16. Vorob’eva OV, Kamchatnov PR, Rachin AP. Efficacy and safety of the novel neurotropic drug Divaza in combination therapy of chronic cerebral ischemia. Effective pharmacotherapy. 2014;31:42-48. (In Russ.)
  17. Chukanova EI, Bogolepova AN, Chukanova AS. An experience of using divasa in the treatment of cerebrovascular insufficiency Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2015;115(6):110-114. (In Russ.) https://doi.org/10.17116/jnevro201511561110-114
  18. Dadasheva MN, Taranenko NYu, Agafonov BV. Innovative treatment of cerebrovascular disease in patients with variable arterial hypertension. Practical medicine. 2015;5(90):221-224. (In Russ.)
  19. Mudrova OA, Sokolov NB, Borikov FA. The efficacy of divasa in the early recovery period of ischemic stroke. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2016;116:48-53. PMID: 27296802. (In Russ.)
  20. Parfyonov VA, Verbitskaya SV. Secondary prevention of ischemic stroke and cognitive impairment. Medical council. 2016;11:6-12. (In Russ.) https://doi.org/10.21518/2079-701x-2016-11-18-24
  21. Fateeva VV, Kolokolov OV, Zakharova NB, Maleina AYu, Abramova TP, Fisun AV, Kolokolova AM, Makarov NS. Disorders in sleep and cognitive functions as representations of chronic cerebral ischemia and pathogenic basis for their correction. Treating doctor. 2016;5:18-23. (In Russ.)
  22. Fateeva VV, Shumakher GI, Vorob’eva EN, Khoreva MA, Voskanyan LR. The efficacy and safety of drug therapy divaza in patients with chronic cerebral ischemia. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2017;117(2):32-37. (In Russ.) https://doi.org/10.17116/jnevro20171172132-37

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.